Order Fat Burning Steroid Hormone Lorcaserin Hydrochloride for Human Weight Loss
|FOB Price:||US $0.1 / g|
|Min. Order:||1 g|
|Min. Order||FOB Price|
|1 g||US $0.1/ g|
|Port:||Hong Kong, Hong Kong|
|Production Capacity:||800kg/Month to 1ton/Month|
|Payment Terms:||T/T, Western Union, Money Gram, bitcoins|
- Model NO.: CAS 856681-05-5
- Customized: Customized
- Suitable for: Elderly, Children, Adult, for All
- Purity: >99%
- CAS: 616202-92-7
- Products Quality: 99.2%
- Storage: Lorcaserin Should Be Stored in a Well-Closed Cont
- Payment Methods: Western Union, T/T, Bitcoins, Moneygram
- Usages: Fat Burning Obesity
- Transport Package: Foil Packaging: Exquisite Fake Packaging
- Origin: HK China
- Powder: Yes
- Certification: GMP, HSE, ISO 9001, USP, BP, SGS
- State: Solid
- Lorcaserin Hydrochloride: Weight Loss Obesity
- Mf: C11h14cln
- Shelf Life: 3 Years
- Shipping Express: EMS.TNT, UPS, FedEx, DHL
- Delivery Time: 3 to 6 Days
- Trademark: SGS ISO9001
- Specification: 99%
- HS Code: 3001
Product Name: Lorcaserin Hydrochloride
Alias: (1R) -8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine hydrochloride; APD 356; APD-356; UNII-0QJF08GDPE; Lorcaserin HCl; (R) - 1H-3-Benzazepine, 8-Chloro-2,3,4,5-Tetrahydro-1-Methyl-, Hydrochloride
Molecular Formula: C11H14ClN · ClH
Molecular Weight: 232.1525
Chemical Property:White Powder
payment methods:Western Union,T/T,Bitcoins,MoneyGram,Alipay,paypal.
Usage:Lorqess is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic
Weight Loss Steroids Lorcaserin Hydrochloride With 99% Purity Gear Steroid Powder
Detailed Descriptions: Lorcaserin hydrocloride : Fat loss:
What is lorcaserin:
Lorcaserin affects chemicals in the brain that affect appetite.
Lorcaserin is used together with diet and exercise to treat obesity
Lorcaserin is sometimes used to treat obesity that may be related to diabetes, high cholesterol, or high blood pressure.
Lorcaserin will not treat any underlying condition you have (such as heart disease, diabetes, high blood pressure). Keep taking any other medications your doctor has prescribed to treat these conditions.
Lorcaserin may also be used for purposes not listed in this medication guide.
Lorcaserin Hydrochloride is an FDA-approved prescription weight-loss medication that, when used with diet and exercise, can help some overweight? adults with a weight-related medical problem, or obese adults, lose weight and keep it off. It is not known if Lorcaserin Hydrochloride when taken with other prescription, over-the-counter, or herbal weight-loss products is safe and effective. It is not known if Lorcaserin Hydrochloride changes your risk of heart problems, stroke, or death due to heart problems or stroke.
How should I take lorcaserin:
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
The usual dose of lorcaserin is 1 tablet 2 times each day. Follow your doctor's instructions.
You may take lorcaserin with or without food.
You should lose at least 5% of your starting weight during the first 12 weeks of taking lorcaserin and eating a low calorie diet. Tell your doctor if you do not lose at least 5% of your starting weight after taking the medication for 12 weeks
Lorcaserin is only part of a complete program of treatment that also includes diet, exercise, weight control, and possibly testing your blood sugar. Follow your diet, medication, and exercise routines very closely.
Store at room temperature away from moisture and heat.
Keep track of the amount of medicine used from each new bottle. Lorcaserin is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription.
Do not share lorcaserin with another person. Keep the medication in a place where others cannot get to it
What should I avoid while taking lorcaserin:
This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.
Do not take any other prescription or over-the-counter weight-loss products without your doctor's advice
Avoid taking cough and cold or allergy medications while taking lorcaserin.
The FDA approval of Lorcaserin Hydrochloride was based on the results of three randomized, double-blind, placebo-controlled trials with durations ranging from 52 to 104 weeks. Study 1 and Study 2 were conducted in adults (n=3182, n=4008; respectively) without type II diabetes, and Study 3 was conducted in adults (n=604) with type II diabetes. All subjects were administered Lorcaserin Hydrochloride 10mg twice daily. The primary endpoint for each study was weight loss at one year as assessed by percent of subjects achieving greater than or equal to 5% weight loss, percent of subjects achieving greater than or equal to 10% weight loss, and mean weight change. Lorcaserin Hydrochloride was administered in conjuction with one-on-one instruction for reduced-calorie diet and exercise counseling at the first dose and at every four weeks during the trials. Study 1 was a two-year trial, and Study 2 and Study 3 were one-year trials. Statistical significance was achieved in each group of Lorcaserin Hydrochloride treated subjects compared to placebo upon evaluation of 5% weight loss or greater.
Lorcaserin dosing information:
Usual Adult Dose for Weight Loss:
10 mg orally twice per day
Comments: Response to therapy should be evaluated by week 12. If a patient has not lost at least 5% of baseline body weight, discontinue this drug as it is unlikely the patient will achieve and sustain clinically meaningful weight loss with continued treatment.
Use: Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) OR 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.
Adverse reactions associated with the non-diabetic use of Lorcaserin Hydrochloride may include, but are not limited to, the following:
Mechanism of Action:
Lorcaserin Hydrochloride (lorcaserin hydrochloride) is a serotonin 2C receptor agonist. While the complete mechanism of action is not entirely understood, it is believed to decrease food consumption and promote satiety by selectively activating 5-HT2C receptors on anorexigenic pro-opiomelanocortin neurons located in the hypothalamus.
|Description||White or almost white crystalline powder||White crystalline powder|
|Loss of drying||≤1.0%||0.5%|
|TLC||Only one spot||Only one spot|
|Conclusion||It complies with the USP 32.|
White to kind of white powder
Kind of white powder
Soluble in methanol
Residue on Ignition
Up to the Standard USP 32.
Why choose our product:
Our advantage is getting freight directly from manufactory thus avoiding extra cost on the products.
We could make our price discount if you place a substantial order with us.
We guarantee the lower price with high quality and purity on each vial and willensure the schedule delivery in accordance with your requirements.After 10 years fight on trading, we have got many customers and earn prestige all over the world.
How to Order:
1.Tell us your poduct name, quantity, delivery time you need and other special requirements if any.
2.Production will be arranged to ship after you order online.
3.Accept the payment by Western union, Monygram and Paypal
4 Shipping Method: Fedex,DHL, EMS, UPS, and TNT.
5. Shipping time. 3-5 days for Fedex/DHL/UPS/TNT, 5-12 days for EMS.
Breast Cancer Therapy: Right On Target
Lorcaserin Hydrochloride can be taken with or without food.
Response to therapy should be evaluated by week 12. If a patient has not lost at least 5% of baseline body weight, discontinue Lorcaserin Hydrochloride, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment [see Clinical Studies.
BMI is calculated by dividing weight in kg by height in meters squared.
A BMI chart for height in inches and weight in pounds is provided below:
Warnings and Precautions
Serotonin Syndrome or Neuroleptic Malignant Syndromelike Reactions
Lorcaserin Hydrochloride is a serotonergic drug. The development of a potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported during use of serotonergic drugs, including, but not limited to, selective serotonin-norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors , tricyclic antidepressants, bupropion, triptans, dietary supplements such as St. John's Wort and tryptophan, drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors , dextromethorphan, lithium, antipsychotics or other dopamine antagonists, particularly when used in combination [see Drug Interactions.
Serotonin syndrome symptoms may include mental status changes , agitation, hallucinations, coma, autonomic instability, tachycardia, labile blood pressure, hyperthermia, neuromuscular aberrations, hyperreflexia, incoordination) and/or gastrointestinal symptoms nausea, vomiting, diarrhea. Serotonin syndrome, in its most severe form, can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms.
The safety of Lorcaserin Hydrochloride when coadministered with other serotonergic or antidopaminergic agents, including antipsychotics, or drugs that impair metabolism of serotonin, including MAOIs, has not been systematically evaluated and has not been established.
If concomitant administration of Lorcaserin Hydrochloride with an agent that affects the serotonergic neurotransmitter system is clinically warranted, extreme caution and careful observation of the patient is advised, particularly during treatment initiation and dose increases. Treatment with Lorcaserin Hydrochloride and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated [see Adverse Reactions
Valvular Heart Disease:
Regurgitant cardiac valvular disease, primarily affecting the mitral and/or aortic valves, has been reported in patients who took serotonergic drugs with 5-HT2B receptor agonist activity. The etiology of the regurgitant valvular disease is thought to be activation of 5-HT2B receptors on cardiac interstitial cells. At therapeutic concentrations, Lorcaserin Hydrochloride is selective for 5-HT2C receptors as compared to 5-HT2B receptors. In clinical trials of 1-year duration, 2.4% of patients receiving Lorcaserin Hydrochloride and 2.0% of patients receiving placebo developed echocardiographic criteria for valvular regurgitation at one year (mild or greater aortic regurgitation and/or moderate or greater mitral regurgitation): none of these patients was symptomatic see Adverse Reactions see Clinical Pharmacology.
Lorcaserin Hydrochloride has not been studied in patients with congestive heart failure or hemodynamically-significant valvular heart disease. Preliminary data suggest that 5HT2B receptors may be overexpressed in congestive heart failure, Therefore, Lorcaserin Hydrochloride should be used with caution in patients with congestive heart failure.
Lorcaserin Hydrochloride should not be used in combination with serotonergic and dopaminergic drugs that are potent 5-HT2B receptor agonists and are known to increase the risk for cardiac valvulopathy, cabergoline.
Patients who develop signs or symptoms of valvular heart disease, including dyspnea, dependent edema, congestive heart failure, or a new cardiac murmur while being treated with Lorcaserin Hydrochloride should be evaluated and discontinuation of Lorcaserin Hydrochloride should be considered.
In clinical trials of at least one year in duration, impairments in attention and memory were reported adverse reactions associated with 1.9% of patients treated with Lorcaserin Hydrochloride and 0.5% of patients treated with placebo, and led to discontinuation in 0.3% and 0.1% of these patients, respectively. Other reported adverse reactions associated with Lorcaserin Hydrochloride in clinical trials included confusion, somnolence, and fatigue [see Adverse Reactions .
Since Lorcaserin Hydrochloride has the potential to impair cognitive function, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Lorcaserin Hydrochloride therapy does not affect them adversely [see Patient Counseling Information .
Events of euphoria, hallucination, and dissociation were seen with Lorcaserin Hydrochloride at supratherapeutic doses in short-term studies [see Adverse Reactions , Drug Abuse and Dependence, and Overdosage . In clinical trials of at least 1-year in duration, 6 patients 0.2% treated with Lorcaserin Hydrochloride developed euphoria, as compared with 1 patient0.1% treated with placebo. Doses of Belviq should not exceed 10 mg twice a day.
Some drugs that target the central nervous system have been associated with depression or suicidal ideation. Patients treated with Lorcaserin Hydrochloride should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Belviq in patients who experience suicidal thoughts or behaviors see Adverse Reactions.
Potential Risk of Hypoglycemia in Patients with Type 2 Diabetes Mellitus on Anti-diabetic Therapy
Weight loss may increase the risk of hypoglycemia in patients with type 2 diabetes mellitus treated with insulin and/or insulin secretagogues (e.g., sulfonylureas); hypoglycemia was observed in clinical trials with Lorcaserin Hydrochloride. Belviq has not been studied in combination with insulin. Measurement of blood glucose levels prior to starting Belviq and during Belviq treatment is recommended in patients with type 2 diabetes. Decreases in medication doses for anti-diabetic medications which are non-glucose-dependent should be considered to mitigate the risk of hypoglycemia. If a patient develops hypoglycemia after starting Belviq, appropriate changes should be made to the anti-diabetic drug regimen see Adverse Reactions .
Priapism (painful erections greater than 6 hours in duration is a potential effect of 5-HT2C receptor agonism.
If not treated promptly, priapism can result in irreversible damage to the erectile tissue. Men who have an erection lasting greater than 4 hours, whether painful or not, should immediately discontinue the drug and seek emergency medical attention.
Lorcaserin Hydrochloride should be used with caution in men who have conditions that might predispose them to priapisms, sickle cell anemia, multiple myeloma, or leukemia), or in men with anatomical deformation of the penis, angulation, cavernosal fibrosis, or Peyronie's disease. There is limited experience with the combination of Lorcaserin Hydrochloride and medication indicated for erectile dysfunction , phosphodiesterase type 5 inhibitors). Therefore, the combination of Lorcaserin Hydrochloride and these medications should be used with caution.
Heart Rate Decreases
In clinical trials of at least 1-year in duration, the mean change in heart rate was -1.2 beats per minute in Lorcaserin Hcl and -0.4 bpm in placebo-treated patients without diabetes and -2.0 beats per minute (bpm) inLorcaserin Hcl and -0.4 bpm in placebo-treated patients with type 2 diabetes. The incidence of HR less than 50 bpm was 5.3% in Lorcaserin Hcl and 3.2% in placebo-treated patients without diabetes and 3.6% in Lorcaserin Hcl and 2.0% in placebo-treated patients with type 2 diabetes. In the combined population, adverse reactions of bradycardia occurred in 0.3% of Lorcaserin Hcl and 0.1% of placebo-treated patients. Use with caution in patients with bradycardia or a history of heart block greater than first degree.
In clinical trials of at least one year in duration, adverse reactions of decreases in white blood cell count including leukopenia, lymphopenia, neutropenia, and decreased white cell count) were reported in 0.4% of patients treated with Lorcaserin Hcl as compared to 0.2% of patients treated with placebo. Adverse reactions of decreases in red blood cell count including anemia and decreases in hemoglobin and hematocrit) were reported by 1.3% of patients treated with Lorcaserin Hcl as compared to 1.2% treated with placebo see Adverse Reactions . Consider periodic monitoring of complete blood count during treatment with Lorcaserin Hcl.
Lorcaserin moderately elevates prolactin levels. In a subset of placebo-controlled clinical trials of at least one year in duration, elevations of prolactin greater than the upper limit of normal, two times the upper limit of normal, and five times the upper limit of normal, measured both before and 2 hours after dosing, occurred in 6.7%, 1.7%, and 0.1% of Lorcaserin Hcl -treated patients and 4.8%, 0.8%, and 0.0% of placebo-treated patients, respectively [see Adverse Reactions Prolactin should be measured when symptoms and signs of prolactin excess are suspected , galactorrhea, gynecomastia. There was one patient treated with Lorcaserin Hcl who developed a prolactinoma during the trial. The relationship of Lorcaserin Hcl to the prolactinoma in this patient is unknown.
Certain centrally-acting weight loss agents that act on the serotonin system have been associated with pulmonary hypertension, a rare but lethal disease. Because of the low incidence of this disease, the clinical trial experience with Lorcaserin Hcl is inadequate to determine if Lorcaserin Hcl increases the risk for pulmonary hypertension.